Quinoline derivatives as TAM RTK inhibitors
US10934274B2 · kind B2 · utility
0Cited by
1References
16Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 14, 2016 |
| Grant date | Mar 2, 2021 |
| Priority date | — |
| Expiry date | Apr 14, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to novel compounds which are inhibitors of TAM (Axl, Mer and Tyro 3) and/or Met family receptor tyrosine kinases (RTKs). These compounds are suitable for the treatment of disorders associated with, accompanied by, caused by or induced by a receptor of the TAM family, in particular a hyperfunction thereof. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly immune-suppressive cancer, refractory cancer and cancer metastases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.